...
首页> 外文期刊>Annals of Internal Medicine >Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery a systematic review
【24h】

Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery a systematic review

机译:在大型骨科手术中延长与标准时间静脉血栓预防的系统评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: The optimal duration of thromboprophylaxis after major orthopedic surgery is unclear. Purpose: To compare the benefits and harms of prolonged versus standard-duration thromboprophylaxis after major orthopedic surgery in adults. Data Sources: Cochrane Central Register of Controlled Trials and Scopus from 1980 to July 2011 and MEDLINE from 1980 through November 2011, without language restrictions. Study Selection: Randomized trials reporting thromboembolic or bleeding outcomes that compared prolonged (≥21 days) with standard-duration (7 to 10 days) thromboprophylaxis. Data Abstraction: Two independent reviewers abstracted data and rated study quality and strength of evidence. Data Synthesis: Eight randomized, controlled trials (3 good-quality and 5 fair-quality) met the inclusion criteria. High-strength evidence showed that compared with standard-duration therapy, prolonged prophylaxis resulted in fewer cases of pulmonary embolism (PE) (5 trials; odds ratio [OR], 0.14 [95% CI, 0.04 to 0.47]; absolute risk reduction [ARR], 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [RR], 0.48 [CI, 0.31 to 0.75]; ARR, 5.8%), symptomatic DVT (4 trials; OR, 0.36 [CI, 0.16 to 0.81]; ARR, 1.5%), and proximal DVT (6 trials; RR, 0.29 [CI, 0.16 to 0.52]; ARR, 7.1%). Moderate-strength evidence showed fewer symptomatic objectively confirmed episodes of venous thromboembolism (4 trials; RR, 0.38 [CI, 0.19 to 0.77]; ARR, 5.7%), nonfatal PE (4 trials; OR, 0.13 [CI, 0.03 to 0.54]; ARR, 0.7%), and DVT (7 trials; RR, 0.37 [CI, 0.21 to 0.64]; ARR, 12.1%) with prolonged prophylaxis. High-strength evidence showed more minor bleeding events with prolonged prophylaxis (OR, 2.44 [CI, 1.41 to 4.20]; absolute risk increase, 6.3%), and insufficient evidence from 1 trial on hip fracture surgery suggested more surgical-site bleeding events (OR, 7.55 [CI, 1.51 to 37.64]) with prolonged prophylaxis. Limitations: Data relevant to knee replacement or hip fracture surgery were scant and insufficient. Most trials had few events; the strength of evidence ratings that were used may not adequately capture uncertainty in such situations. Conclusion: Prolonged prophylaxis decreases the risk for venous thromboembolism, PE, and DVT while increasing the risk for minor bleeding in patients undergoing total hip replacement. Primary Funding Source: Agency for Healthcare Research and Quality.
机译:背景:大型骨科手术后预防血栓的最佳持续时间尚不清楚。目的:比较成年人大型骨科手术后长期和标准持续时间预防血栓形成的利弊。数据来源:1980年至2011年7月的Cochrane对照试验和Scopus中央登记册,以及1980年至2011年11月的MEDLINE,无语言限制。研究选择:随机试验报告血栓栓塞或出血结果与延长(≥21天)与标准持续时间(7至10天)的血栓预防相比。数据抽象:两名独立的审稿人对数据进行抽象,并对研究质量和证据强度进行评级。数据综合:八项随机,对照试验(3项质量良好和5项公平质量)符合纳入标准。高强度证据表明,与标准持续时间疗法相比,延长预防时间可减少肺栓塞(PE)病例(5个试验;比值比[OR]为0.14 [95%CI,0.04至0.47];绝对危险度降低[ ARR],0.8%),无症状深静脉血栓形成(DVT)(4个试验;相对危险度[RR],0.48 [CI,0.31至0.75]; ARR,5.8%),有症状DVT(4个试验; OR,0.36 [CI] ,0.16至0.81]; ARR,1.5%)和近端DVT(6个试验; RR,0.29 [CI,0.16至0.52]; ARR,7.1%)。中等强度的证据显示经客观客观确认的静脉血栓栓塞发作较少(4个试验; RR,0.38 [CI,0.19至0.77]; ARR,5.7%),非致命性PE(4个试验; OR,0.13 [CI,0.03至0.54] ; ARR,0.7%)和DVT(7个试验; RR,0.37 [CI,0.21至0.64]; ARR,12.1%),且预防时间较长。高强度证据显示,长期预防可导致更多的轻微出血事件(OR为2.44 [CI,1.41至4.20];绝对风险增加,为6.3%),而一项髋部骨折手术试验的证据不足则表明更多的手术部位出血事件(或7.55 [CI,1.51至37.64]),且预防时间长。局限性:与膝关节置换术或髋部骨折手术有关的数据很少且不足。大多数审判​​没有什么事件。在这种情况下,所使用的证据评级的强度可能不足以捕捉不确定性。结论:长时间的预防可降低全髋置换患者静脉血栓栓塞,PE和DVT的风险,同时增加轻微出血的风险。主要资金来源:卫生保健研究与质量局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号